Zydus Lifesciences jumps on getting in principle acceptability from WHO for ZyVac TCV
Zydus Lifesciences is currently trading at Rs. 1015.00, up by 26.80 points or 2.71% from its previous closing of Rs. 988.20 on the BSE.
The scrip opened at Rs. 981.05 and has touched a high and low of Rs. 1016.35 and Rs. 981.05 respectively. So far 33456 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1323.90 on 09-Aug-2024 and a 52 week low of Rs. 567.85 on 26-Oct-2023.
Last one week high and low of the scrip stood at Rs. 1030.15 and Rs. 981.05 respectively. The current market cap of the company is Rs. 101986.85 crore.
The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 18.17% and 6.85% respectively.
Zydus Lifesciences has received in principle acceptability from World Health Organisation (WHO) for ZyVac TCV. ZyVac TCV is now eligible for purchase by United Nations (UN) agencies. ZyVac TCV is indigenously developed and manufactured at the Zydus Biotech Park, Ahmedabad.
ZyVac TCV is indicated for active immunization against Salmonella typhi infection in the age group of 6 months to 65 years. This prequalification for ZyVac TCV makes it eligible to be part of UN agencies procurement programme. Annually over 150 million doses of the typhoid conjugate vaccine is procured by UN agencies to prevent this infectious disease in geographies where it is most prevalent, such as India, Africa and Southeast Asia.
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.
